Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618571 | 0.90 | CHRM1 (0.68) | CHRM1CHRM2CHRM5 | |
| SCHEMBL22472937 | 0.90 | CHRM1 (0.55) | CHRM1 | |
| SCHEMBL15618702 | 0.89 | CHRM1 (0.70) | CHRM1CHRM2CHRM5 | |
| SCHEMBL21597926 | 0.86 | CHRM1 (0.63) | CHRM1CHRM2CHRM5 | |
| SCHEMBL15630184 | 0.83 | CHRM1 (0.72) | CHRM1ALDH1A1GAACHRM5 | |
| SCHEMBL14978907 | 0.83 | CHRM1 (0.93) | CHRM1ALDH1A1GAASMN1; SMN2CHRM2 | |
| SCHEMBL15618929 | 0.82 | CHRM1 (0.63) | CHRM1ALDH1A1GAASMN1; SMN2CHRM2 | |
| Htl-9936 SCHEMBL14964900 | 0.80 | CHRM1 (1.00) | CHRM1ALDH1A1GAACHRM2 | |
| Htl-9936 SCHEMBL14978774 | 0.80 | CHRM1 (1.00) | CHRM1ALDH1A1GAACHRM2 | |
| Htl-9936 SCHEMBL16217938 | 0.80 | CHRM1 (1.00) | CHRM1ALDH1A1GAACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885ALDH1A1 2016/4885GAA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.